IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. IN8bio’s current pipeline centers on cell-based immunotherapies designed to target solid and hematologic tumors, with programs spanning allogeneic, autologous, iPSC-derived, and genetically modified approaches. Its lead and clinical programs include candidates being studied in glioblastoma and leukemia settings, reflecting the company’s emphasis on difficult-to-treat cancers and unmet medical needs. IN8bio also advances a T cell engager platform intended to broaden the reach of its immunotherapy portfolio across oncology and autoimmune indications. Based in New York, IN8bio plays a niche role in the biotechnology market as a developer of next-generation cellular medicines.
Website350 5th Avenue
New York, NY, 10118
United States
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares of its common stock. The award was approved by the Compensation Committee of the C
Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026Presented updated data at ASCO 2026 demonstrating median overall survival (mOS) exceeding 19.5 months and still climbing, across all patients with newly diagnosed glioblastoma (GBM) treated with repeat-dosing of DeltEx™ Drug Resistant Immunotherapy (DRI)P
Investors talking about INAB also mention
What share of all stock conversation is about INAB?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% 0 |
Of the messages about INAB that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% +44.44 | 92.23% +9.82 | ||
| Bearish | — | — | 0% -44.44 | 7.77% -9.82 |
Of the messages about INAB that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 100% | 88.4% | ||
| Technical Analysis | — | 0% | 0% | 11.05% | ||
| Analysts | — | 0% | 0% | 0% | ||
| Controversies | — | 0% | 0% | 0% | ||
| Earnings | — | 0% | 0% | 0.55% | ||
| Macro | — | 0% | 0% | 0% |
Of the messages about INAB, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 50% | 72.73% | 50.49% | ||
| Newcomers | — | 50% | 27.27% | 49.51% |